Comparative Pharmacology
Head-to-head clinical analysis: OBREDON versus TENORMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OBREDON versus TENORMIN.
OBREDON vs TENORMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clonidine is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, leading to decreased peripheral vascular resistance and blood pressure.
Selective beta-1 adrenergic receptor antagonist; blocks catecholamine effects at beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Adults: 10 mg orally once daily. For patients requiring more rapid relief, initial dose of 20 mg once daily may be used; switch to 10 mg once daily after 4 to 8 weeks.
Hypertension: 50 mg orally once daily; may increase to 100 mg once daily. Angina: 50 mg orally once daily; may increase to 100 mg once daily. Acute MI: 5 mg IV over 5 minutes, followed by 50 mg orally 15 minutes later, then 50 mg orally 12 hours later, then 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of 30 hours (range 24-36 hours), supporting once-daily dosing in chronic therapy.
6-7 hours (terminal); prolonged to 16-27 hours in renal impairment (CrCl <35 mL/min).
Approximately 75% renal excretion as unchanged drug and metabolites, with 25% fecal elimination via biliary secretion.
Renal elimination of unchanged drug (40-50%) and hepatic metabolism to inactive metabolites excreted in urine; <5% fecal.
Category C
Category C
Beta blocker/alpha blocker
Beta blocker